Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Overview:
As per MRFR analysis, the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size was estimated at 0.08 (USD Billion) in 2023. The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Industry is expected to grow from 0.09(USD Billion) in 2024 to 0.15 (USD Billion) by 2032. The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market CAGR (growth rate) is expected to be around 6.21% during the forecast period (2024 - 2032).
Key Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Trends Highlighted
Key market drivers for the Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2) Treatment Market include the rising prevalence of PFIC2, growing awareness of the disease, and advancements in therapeutic approaches. The market is witnessing a surge in demand for effective and innovative treatments due to the unmet medical needs of patients. Opportunities for growth lie in the development of novel therapies, such as gene therapies and targeted therapies, that address the underlying genetic defects causing PFIC2. Recent trends indicate a shift towards personalized medicine, with a focus on tailored treatment regimens based on individual patient characteristics. The market is expected to continue expanding as research efforts yield promising new treatment options and improve patient outcomes.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drivers
Rising Prevalence of Liver Diseases
PFIC2 is a rare genetic liver disease affecting both infants and children. The disease is due to the deposition of bile in the liver, thereby damaging it, and eventually can lead to cirrhosis. The rising number of liver diseases, among them PFIC2, has increased the size of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Industry. WHO reported that liver diseases were the 11th leading cause of death and responsible for about 1.5 million deaths annually.Liver diseases are on the rise because of a number of factors which is contributing to the increase of the death rate. Therefore, this growing number of diseases is a major driver of the growth of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Industry. The factors causing liver diseases include obesity, diabetes, and hepatitis.
Increasing Awareness of PFIC2
Another key driver of the growth of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Industry is the increase in awareness regarding PFIC2. Previously, PFIC2 was commonly misdiagnosed or remained undiagnosed. However, with advancements in diagnostic tests for PFIC2 and the growing knowledge about the disease, the number of patients diagnosed with PFIC2 has increased. This, in turn, has helped drive the demand for the appropriate treatment options, contributing to the growth of the market.
Growing Pipeline of PFIC2 Treatments
The development of some new drugs and therapies for the treatment of PFIC2 is also one of the major factors that are driving the growth of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Industry. The number of new drugs and therapies being produced for the PFIC2 is increasing, and it is expected that these will become the best possible options available for patients with PFIC2.
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Segment Insights:
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Treatment Type Insights
The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is segmented on the basis of Treatment Type into Medication, Liver Transplantation, and Other Treatments. The Medication segment is the most prominent one in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market. Progressive familial intrahepatic cholestasis type 2 can be treated using medications including ursodeoxycholic acid, obeticholic acid, and fibrates. Liver transplantation entails a surgical procedure in which the diseased liver of a patient is replaced with the liver of a healthy donor.Liver transplantation is a last resort treatment for patients who suffer from the end stage of Progressive Familial Intrahepatic Cholestasis Type 2. The other treatments include supportive care, such as dietary modifications, cholestyramine, and plasmapheresis, that are required to be adopted by the patients. The medication segment is anticipated to grow at a steady pace in the future market owing to more adoption of ursodeoxycholic acid and the development of new medications. Liver transplantation is anticipated to grow at a stable rate in the future, while the other treatment is expected to grow at a moderate pace.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drug Class Insights
Bile Acid Resins, Ursodeoxycholic Acid, and Others constitute the drug class segment in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market. Bile Acid Resins accounted for the largest revenue share in 2023, owing to their efficacy in reducing pruritus and improving liver function. Ursodeoxycholic Acid is expected to witness the fastest growth rate during the forecast period due to its ability to improve bile flow and reduce liver inflammation. Others, which include experimental and emerging therapies, are anticipated to contribute a significant share to the market growth. The increasing prevalence of Progressive Familial Intrahepatic Cholestasis Type 2, coupled with the rising demand for effective treatment options, is driving the growth of the drug class segment.
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Route of Administration Insights
The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market segmentation by Route of Administration includes Oral, Intravenous, and Others. The Oral segment is anticipated to hold the largest share of the market in 2023, accounting for around 65%. This dominance can be attributed to the ease of administration, patient convenience, and cost-effectiveness of oral medications. The Intravenous segment is projected to witness steady growth over the forecast period, owing to the increasing adoption of injectable therapies for severe cases of Progressive Familial Intrahepatic Cholestasis Type 2.The Others segment, which includes topical and transdermal formulations, is expected to gain traction due to the growing demand for non-invasive and localized treatment options. The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market revenue for the Oral segment is estimated to reach USD 0.34 billion by 2032, while the Intravenous segment is projected to generate USD 0.15 billion by the same year. These insights are crucial for market players to strategize their product portfolios and cater to the evolving needs of patients with Progressive Familial Intrahepatic Cholestasis Type 2.
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Severity of Disease Insights
The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is segmented by severity of disease into mild, moderate, and severe. Among these segments, the severe segment is expected to hold the largest market share, accounting for over 50% of the global market revenue in 2023. This is due to the high prevalence of severe cases of Progressive Familial Intrahepatic Cholestasis Type 2, which require more intensive and expensive treatment. The moderate segment is expected to grow at the fastest rate over the forecast period as more patients are diagnosed with this type of disease. The mild segment is expected to account for the smallest market share, as these patients typically require less intensive and expensive treatment.
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Regional Insights
The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is segmented into North America, Europe, APAC, South America, and MEA. The regional market segmentation provides insights into the market's growth potential, size, and key trends.
North America is expected to hold the largest share of the global market in 2023, owing to the presence of key market players and a high prevalence of PFIC2. Europe is expected to witness steady growth, driven by increasing awareness about PFIC2 and the availability of advanced treatment options.APAC is anticipated to register a significant growth rate, due to rising healthcare expenditure and increasing investment in research and development activities. South America and MEA are expected to experience moderate growth, owing to limited access to specialized healthcare facilities and lower healthcare expenditure.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Key Players And Competitive Insights:
Major players in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market industry are actively involved in research and development activities to strengthen their product portfolios and gain a competitive edge. Leading Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market players are focused on expanding their geographical presence and forming strategic alliances to cater to the growing patient population.
The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is witnessing a surge in mergers and acquisitions as companies seek to consolidate their market position and gain access to innovative technologies. Key players are also investing in the development of novel treatment approaches, such as gene therapy and stem cell therapy, to address unmet medical needs in the treatment of Progressive Familial Intrahepatic Cholestasis Type 2.A leading company in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is focused on providing comprehensive care to patients with cholestatic liver diseases. The company offers a range of products and services, including diagnostic tests, therapies, and support programs. It has a strong presence in major markets and is actively expanding its geographical reach through strategic collaborations and acquisitions. The company is committed to investing in research and development to discover and develop innovative treatments for Progressive Familial Intrahepatic Cholestasis Type 2 and other cholestatic liver diseases.A prominent competitor in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is known for its expertise in the development and commercialization of orphan drugs. The company has a robust pipeline of potential therapies for rare diseases, including Progressive Familial Intrahepatic Cholestasis Type 2. It is focused on leveraging its strong commercial infrastructure and partnerships with patient advocacy groups to drive market penetration and improve patient access to its treatments. The company is committed to working closely with healthcare professionals and researchers to advance the understanding and management of Progressive Familial Intrahepatic Cholestasis Type 2 and other rare liver diseases.
Key Companies in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Include:
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Industry Developments
The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is projected to grow from USD 0.09 billion in 2024 to USD 0.15 billion by 2032, exhibiting a CAGR of 6.21%. This growth is attributed to the rising prevalence of the disease, increasing awareness of treatment options, and the development of novel therapies.Recent news developments include the approval of obeticholic acid by the FDA in 2023 for the treatment of PFIC2 and the initiation of clinical trials for several promising new therapies. Major players in the market include Albireo Pharma, Inc., Mirum Pharmaceuticals, Inc., and Gilead Sciences, Inc. Key market dynamics include strategic collaborations and partnerships between pharmaceutical companies and research institutions to accelerate drug development and commercialization.
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Segmentation Insights
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Treatment Type Outlook
- Medication
- Liver Transplantation
- Other Treatments
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drug Class Outlook
- Bile Acid Resins
- Ursodeoxycholic Acid
- Others
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Route of Administration Outlook
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Severity of Disease Outlook
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2023 |
0.08(USD Billion) |
| Market Size 2024 |
0.09(USD Billion) |
| Market Size 2032 |
0.15(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
6.21% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Pfizer, Novartis, Johnson Johnson, Genfit, Roche, Merck, Intercept Pharmaceuticals, GlaxoSmithKline, Bristol Myers Squibb, Eli Lilly, Albireo Pharma, Madrigal Pharmaceuticals, Bayer, BridgeBio Pharma, Mirum Pharmaceuticals |
| Segments Covered |
Treatment Type, Drug Class, Route of Administration, Severity of Disease, Regional |
| Key Market Opportunities |
Targeted therapies Novel drug discovery Genetic testing amp screening Artificial intelligence Telehealth |
| Key Market Dynamics |
Growing prevalence of PFIC2 Launch of novel therapies Rise in government initiatives Expansion of patient support organizations Increasing awareness about PFIC2. |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is expected to reach USD 0.15 billion by 2032, exhibiting a CAGR of 6.21% during the forecast period (2024-2032).
North America is expected to dominate the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, accounting for the largest share due to the high prevalence of the disease and the presence of major market players in the region.
The key growth drivers of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market include the increasing prevalence of the disease, the growing demand for effective treatment options, and the rising healthcare expenditure.
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment is primarily used for the treatment of progressive familial intrahepatic cholestasis type 2, a rare genetic disorder that affects the liver.
The key competitors in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market include Albireo Pharma, Inc., Mirum Pharmaceuticals, Inc., and Novartis AG.
The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is expected to exhibit a CAGR of 6.21% during the forecast period (2024-2032).
The growth of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market may be restrained by the high cost of treatment and the limited number of approved therapies.
The key trends shaping the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market include the growing focus on precision medicine and the development of new therapies.
The challenges faced by the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market include the lack of awareness about the disease and the limited access to treatment in developing countries.
The opportunities for growth in the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market include the rising prevalence of the disease and the increasing demand for effective treatment options.
